These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 17485652)

  • 1. Mitoxantrone for multiple sclerosis causing acute lymphoblastic leukemia.
    Cartwright MS; Jeffery DR; Lewis ZT; Koty PP; Stewart WT; Molnár I
    Neurology; 2007 May; 68(19):1630-1. PubMed ID: 17485652
    [No Abstract]   [Full Text] [Related]  

  • 2. Leukaemia due to mitoxantrone.
    Prescrire Int; 2007 Aug; 16(90):153-6. PubMed ID: 17724842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical study on mitoxantrone contained regimen for treatment of newly diagnosed childhood acute lymphoblastic leukemia].
    Wang WQ; Liu XY; Liu LQ
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2004 Oct; 29(5):602-3. PubMed ID: 16137060
    [No Abstract]   [Full Text] [Related]  

  • 4. Acute promyelocytic leukemia after mitoxantrone therapy for multiple sclerosis.
    Ramkumar B; Chadha MK; Barcos M; Sait SN; Heyman MR; Baer MR
    Cancer Genet Cytogenet; 2008 Apr; 182(2):126-9. PubMed ID: 18406875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitoxantrone and cytosine arabinoside (ARA-C) in adult acute leukemia: an interim report.
    Kansu E; Koc Y; Kars A; Alakavuklar M; Tekuzman G; Firat D
    J Chemother; 1989 Jul; 1(4 Suppl):1268-70. PubMed ID: 16312861
    [No Abstract]   [Full Text] [Related]  

  • 6. Acute promyelocytic leukemia in a patient with multiple sclerosis following treatment with mitoxantrone.
    Novoselac AV; Reddy S; Sanmugarajah J
    Leukemia; 2004 Sep; 18(9):1561-2. PubMed ID: 15215874
    [No Abstract]   [Full Text] [Related]  

  • 7. Toxic non-resorptive internal hydrocephalus as a result of haemorrhagic ventriculitis during induction chemotherapy of Bcr-Abl positive acute lymphoblastic leukaemia.
    Ramadanova K; Hoff H; Gökbuget N; Reuner U; Hamann S; Ehninger G; Schaich M
    Ann Hematol; 2010 Feb; 89(2):221-3. PubMed ID: 19575198
    [No Abstract]   [Full Text] [Related]  

  • 8. Acute myeloid leukaemia induced by mitoxantrone in a multiple sclerosis patient.
    Tanasescu R; Debouverie M; Pittion S; Anxionnat R; Vespignani H
    J Neurol; 2004 Jun; 251(6):762-3. PubMed ID: 15311359
    [No Abstract]   [Full Text] [Related]  

  • 9. [Mitoxantrone for the treatment of patients with multiple sclerosis].
    Komori M; Kondo T; Tanaka M
    Brain Nerve; 2009 May; 61(5):575-80. PubMed ID: 19514518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myelodysplastic syndrome and acute myeloid leukemia after treatment with fludarabine, mitoxantrone, and dexamethasone.
    Au WY; Chan LC; Liang R; Kwong YL
    Am J Hematol; 2006 Jun; 81(6):471-3. PubMed ID: 16680740
    [No Abstract]   [Full Text] [Related]  

  • 11. Mitoxantrone for worsening multiple sclerosis: tolerability, toxicity, adherence and efficacy in the clinical setting.
    Wundes A; Kraft GH; Bowen JD; Gooley TA; Nash RA
    Clin Neurol Neurosurg; 2010 Dec; 112(10):876-82. PubMed ID: 20727669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute promyelocytic leukemic involvement of the optic nerves following mitoxantrone treatment for multiple sclerosis.
    Ko MW; Tamhankar MA; Volpe NJ; Porter D; McGrath C; Galetta SL
    J Neurol Sci; 2008 Oct; 273(1-2):144-7. PubMed ID: 18687447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitoxantrone-induced extravasation.
    Luke E
    Oncol Nurs Forum; 2005 Jan; 32(1):27-9. PubMed ID: 15682531
    [No Abstract]   [Full Text] [Related]  

  • 14. Tolerability and acceptance of prolonged low/delayed mitoxantrone regimens in patients with worsening multiple sclerosis.
    Zecca C; Petrini L; Limoni C; Staedler C; Gobbi C
    Eur Neurol; 2011; 65(1):40-5. PubMed ID: 21196739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A case of acute promyelocytic leukaemia following mitoxantrone treatment of multiple sclerosis.
    Cattaneo C; Almici C; Borlenghi E; Motta M; Rossi G
    Leukemia; 2003 May; 17(5):985-6. PubMed ID: 12750718
    [No Abstract]   [Full Text] [Related]  

  • 16. Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis.
    Vollmer T; Panitch H; Bar-Or A; Dunn J; Freedman MS; Gazda SK; Campagnolo D; Deutsch F; Arnold DL
    Mult Scler; 2008 Jun; 14(5):663-70. PubMed ID: 18424479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapy-related acute leukaemia with Mitoxantrone: what is the risk and can we minimise it?
    Ellis R; Boggild M
    Mult Scler; 2009 Apr; 15(4):505-8. PubMed ID: 19251838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety.
    Zipoli V; Portaccio E; Hakiki B; Siracusa G; Sorbi S; Amato MP
    J Neurol Sci; 2008 Mar; 266(1-2):25-30. PubMed ID: 17870094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitoxantrone in multiple sclerosis.
    Neuhaus O; Kieseier BC; Hartung HP
    Adv Neurol; 2006; 98():293-302. PubMed ID: 16400840
    [No Abstract]   [Full Text] [Related]  

  • 20. Severe cardiac failure in a patient with multiple sclerosis following low-dose mitoxantrone treatment.
    Killestein J; van der Meer ML; Regelink JC; Huijgens PC; Polman CH
    Neurology; 2010 Mar; 74(11):934; author reply 934. PubMed ID: 20231672
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.